Chemokine (CXCL13) as Anew Marker in Diagnosis of SLE
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03752983|
Recruitment Status : Not yet recruiting
First Posted : November 26, 2018
Last Update Posted : January 29, 2019
|Condition or disease||Intervention/treatment|
|Systemic Lupus||Diagnostic Test: blood samples|
Systemic lupus erythematosus (SLE) is systemic autoimmune disease characterized by various immunological abnormalities, including dysregulated activation of both T and B lymphocytes with overt production of autoreactive antibodies . Lupus nephritis (LN) is the most common and serious complication in SLE patients characterized by proteinuria, hematuria, drop glomerular filtration rate, or renal dysfunction . It is known that B lymphocytes are involved in the pathogenesis of systemic lupus erythematosus in autoantibody-dependent mechanisms . The chemokine CXC ligand 13 protein (CXCL13), also known as B cell-attracting chemokine-1 (BAC-1) or B lymphocyte chemoattractant (BLC), is a CXC subtype member of the chemokine superfamily. The receptor of CXCL13 is CXCR5, which is normally expressed on mature B cells and follicular T helper cells (Tfh). It has been demonstrated that CXCL13 is sufficient to induce secondary lymphoid tissues in peripheral organs. It is well known that different chemokines are involved in the pathogenesis of LN by orchestrating proinflammatory microenvironments, recruiting immune cell subsets into the kidney and by inducing local activation of immune effector cells . Local B-cell infiltration and related abnormal expression of ectopic lymphoid tissue (ELT) in the renal tissues of LN mice models was related to the severity of renal impairment .
Of interest, in regions of B cell infiltration a higher expression level of CXCL13 was found. Most B cells in this region expressed the corresponding receptor CXCR5, also supporting the hypothesis that CXCL13 induces B cell infiltration into the kidneys via its receptor CXCR5 .
In one study on 91Caucasian patients, CXCL13 serum levels were correlated with disease activity using the SLE Disease Activity Index (SLEDAI) and to lupus nephritis. It was found that serum CXCL13 levels correlated well with SLEDAI and median CXCL13 concentrations were higher in patients with renal involvement .
|Study Type :||Observational|
|Estimated Enrollment :||86 participants|
|Official Title:||Chemokine CXCL13 as a Marker of Disease Activity in Systemic Lupus Erythematosus|
|Estimated Study Start Date :||March 1, 2019|
|Estimated Primary Completion Date :||March 1, 2020|
|Estimated Study Completion Date :||December 1, 2020|
patients with SLE
Diagnostic Test: blood samples
Diagnostic Test: blood samples
- to measure the level of cxcl13 in SLE [ Time Frame: Baseline ]to differentiate the level of (cxcl13) between healthy individuals and patients with SLE
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03752983
|Contact: Mariam Mohamed, Masterfirstname.lastname@example.org|
|Contact: Wafaa El-Sherif, profeesor||01001861515 ext +20|